PMID: 11921113Mar 29, 2002Paper

Placebo-associated improvements in motor function: comparison of subjective and objective sections of the UPDRS in early Parkinson's disease

Movement Disorders : Official Journal of the Movement Disorder Society
Christopher G GoetzParkinson Study Group

Abstract

The Unified Parkinson's Disease Rating Scale (UPDRS) is primarily composed of an investigator-derived objective rating of motor function and a patient-derived assessment of activities of daily living (ADL). Using a stringent definition of placebo effect, we examined the frequency, temporal development, and stability of improvements during placebo treatment over 6 months in a large placebo-controlled trial of deprenyl and tocopherol in early Parkinson's disease (DATATOP). One hundred ninety-nine subjects received placebo treatment in the randomized, multicenter, placebo-controlled DATATOP study. We compared the baseline UPDRS motor section scores with follow-up scores at 4, 13, and 26 weeks. Placebo-associated improvement was defined as an improvement over baseline score in motor UPDRS of at least 50% or a change in at least two motor items at any one visit by two or more points. Seventeen percent of the 185 subjects who qualified for analysis met the placebo response criteria. The group prevalence of response was steady (7% to 10%) at any one visit without a marked predominance of an early study effect. Older subjects with more motor impairment at baseline were most likely to show a placebo-associated improvement. ADL scores we...Continue Reading

References

Jan 1, 1994·Movement Disorders : Official Journal of the Movement Disorder Society·P Martínez-MartínF Bermejo
Jan 21, 1993·The New England Journal of Medicine·UNKNOWN Parkinson Study Group
Aug 1, 1995·Clinical Neuropharmacology·J P HubbleA Elvin
Mar 1, 1996·Movement Disorders : Official Journal of the Movement Disorder Society·E D LouisS Fahn
Aug 1, 1998·Movement Disorders : Official Journal of the Movement Disorder Society·G T Stebbins, C G Goetz
Mar 26, 1999·Movement Disorders : Official Journal of the Movement Disorder Society·O Lindvall
Feb 19, 2000·Neurology·C G GoetzG T Stebbins

❮ Previous
Next ❯

Citations

Mar 6, 2007·Molecular Imaging and Biology : MIB : the Official Publication of the Academy of Molecular Imaging·Sarah C Christine Lidstone, A Jon Stoessl
Feb 28, 2004·Science and Engineering Ethics·Raúl de la Fuente-Fernández, A Jon Stoessl
Apr 23, 2003·Journal of Fluency Disorders·Alexander M Goberman, Michael Blomgren
Sep 9, 2005·The New England Journal of Medicine·John G Nutt, G Frederick Wooten
Dec 5, 2008·The New England Journal of Medicine·Peter A Lewitt
Nov 14, 2003·The New England Journal of Medicine·Paul KrackPierre Pollak
Jun 24, 2008·Brain : a Journal of Neurology·Barry S Oken
May 15, 2004·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·S PapapetropoulosE Chroni
Oct 14, 2006·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·M HorstinkUNKNOWN Movement Disorder Society-European Section
Oct 14, 2006·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·M HorstinkUNKNOWN Movement Disorder Society-European Section
Nov 18, 2005·Journal of Neurology, Neurosurgery, and Psychiatry·F FregniA Pascual-Leone
Aug 27, 2005·Journal of Neurosurgery·Roy A E Bakay
Jan 6, 2010·Indian Journal of Psychiatry·Chittaranjan Andrade, Rajiv Radhakrishnan
Jul 22, 2010·Expert Opinion on Investigational Drugs·Thomas Müller
Jan 22, 2005·Journal of Evaluation in Clinical Practice·David A StoneTed J Kaptchuk
Apr 7, 2005·Fundamental & Clinical Pharmacology·Hasmet A Hanagasi, Murat Emre
Nov 25, 2014·Eating and Weight Disorders : EWD·Nino Rekhviashvili, Sumati Gupta
Jan 25, 2014·Cortex; a Journal Devoted to the Study of the Nervous System and Behavior·Elisa FrisaldiFabrizio Benedetti
Oct 22, 2008·Expert Opinion on Pharmacotherapy·Lawrence W Elmer, John M Bertoni
Jun 4, 2011·Expert Opinion on Pharmacotherapy·Jennifer G GoldmanChristopher G Goetz
Mar 20, 2008·Expert Opinion on Therapeutic Targets·Jon Stoessl
Jul 1, 2011·Parkinsonism & Related Disorders·Anabela ValadasJoaquim J Ferreira
Apr 20, 2006·Parkinsonism & Related Disorders·M VisserJ J van Hilten
Jun 21, 2005·Pharmacology & Therapeutics·Clifford W Shults
Aug 18, 2004·Journal of Geriatric Psychiatry and Neurology·Dylan P WintHubert H Fernandez
Dec 19, 2016·Drugs·Emma M Coppen, Raymund A C Roos
Oct 10, 2003·Movement Disorders : Official Journal of the Movement Disorder Society·Christopher G GoetzJean A Jaglin
Sep 23, 2003·Movement Disorders : Official Journal of the Movement Disorder Society·Werner Poewe
Jun 20, 2003·Movement Disorders : Official Journal of the Movement Disorder Society·UNKNOWN Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease
Jun 5, 2003·Movement Disorders : Official Journal of the Movement Disorder Society·Gurutz LinazasoroAsier Lasa
Apr 1, 2003·Annals of Neurology·Olivier RascolJean-Louis Montastruc
Jan 5, 2008·Movement Disorders : Official Journal of the Movement Disorder Society·Christopher G GoetzHermann Russ
Sep 20, 2018·Movement Disorders : Official Journal of the Movement Disorder Society·Joaquim J FerreiraTiago A Mestre
May 25, 2006·Movement Disorders : Official Journal of the Movement Disorder Society·Rodrigo MercadoChristopher R Honey
May 5, 2006·Movement Disorders : Official Journal of the Movement Disorder Society·Olivier Rascol
Nov 10, 2006·Movement Disorders : Official Journal of the Movement Disorder Society·Christopher G GoetzHermann Russ
Feb 11, 2016·The Journal of Physiology·Fabrizio BenedettiLeonardo Lopiano
Dec 13, 2018·Chinese Medical Journal·Chun-Feng LiuK Ray Chaudhuri
Jun 2, 2007·Movement Disorders : Official Journal of the Movement Disorder Society·Murat EmreBruno Dubois
Apr 28, 2006·Current Opinion in Psychiatry·Uwe Ehrt, Dag Aarsland
Apr 12, 2005·Movement Disorders : Official Journal of the Movement Disorder Society·Leo Verhagen Metman, Shaun T O'Leary
Apr 12, 2005·Movement Disorders : Official Journal of the Movement Disorder Society·Cheryl Waters
Apr 9, 2005·Movement Disorders : Official Journal of the Movement Disorder Society·Christopher G GoetzCristina Sampaio
Oct 28, 2008·Movement Disorders : Official Journal of the Movement Disorder Society·Madaline B HarrisonG Frederick Wooten
Aug 11, 2005·Movement Disorders : Official Journal of the Movement Disorder Society·Werner Poewe

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.